Skip to content

Exelixis EXEL EV / sales

EV / sales at other companies

Eli Lilly logo
Eli LillyLLY
11.9×-4.0×
Pfizer logo
PfizerPFE
3.5×+0.3×
Summit Therapeutics logo
Summit TherapeuticsSMMT
8,448.1×+8,132×
Incyte logo
IncyteINCY
2.9×+0.6×
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
12.2×+5.7×
BridgeBio Pharma logo
BridgeBio PharmaBBIO
28.9×-18.5×

Other financials

Income statement

See full
Revenue$610.8M+10.0%
Gross profit$590.9M+10.2%
Operating income$251.3M+34.5%
Net income$210.5M+31.9%
EPS (diluted)$0.79+43.6%

Balance sheet

See full
Cash & equivalents$226.2M+23.1%
Total debt$169.5M-9.4%
Total equity$1.9B-9.2%
Total assets$2.6B-8.6%

Cash flow

See full
Operating cash flow$251.8M+19.1%
CapEx$1.5M-48.9%
Free cash flow$250.3M+20.1%

Valuation

See full
Market cap$13.05B+10.1%
Enterprise value$12.99B+9.5%
P/E15.7×-2.8×
P/S5.5×+0.3×

Profitability

See full
Gross margin96.4%-0.3pp
Operating margin39.4%+6.3pp
Net margin35.1%+7.1pp
FCF margin38.6%+2.9pp

Returns & leverage

See full
Return on equity41%+10.8pp
Debt / equity0.1×0.0×
Current ratio3.3×-0.2×

Where this comes from

Calculated from Exelixis’s reported figures.

Based on the most recent quarter.

The official record: Exelixis’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Exelixis's ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Exelixis's EV / sales?
Exelixis (EXEL) reported EV / sales of 4.7× in Q1 2026.
How has Exelixis's EV / sales changed year-over-year?
Exelixis's EV / sales increased by 6.0% year-over-year, from 4.5× to 4.7×.
What is the long-term trend for Exelixis's EV / sales?
Over 5 years (2020 to 2025), Exelixis's EV / sales has grown at a -7.4% compound annual growth rate (CAGR), from 6.8× to 4.7×.
What does EV / sales mean?
What the whole business costs relative to its annual sales.
How do you interpret EV / sales?
A fallback valuation gauge for pre-profit or cyclical firms. Like P/S, only comparable across similar-margin businesses, but it accounts for debt and cash unlike P/S.
How does EV / sales compare across companies?
Compare within a margin cohort; the debt-and-cash adjustment makes it cleaner than P/S for leveraged firms.